Drug Profile


Alternative Names: Ezatiostat HCl; Ezatiostat hydrochloride; Telintra; TLK-199

Latest Information Update: 25 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Telik
  • Developer MabVax Therapeutics; Telik
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutathione S-transferase pi inhibitors; JNK mitogen-activated protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Myelodysplastic syndromes; Neutropenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Aug 2015 No recent reports of development identified - Phase-I for Myelodysplastic syndromes (Combination therapy) in USA (PO)
  • 25 Aug 2015 No recent reports of development identified - Phase-II for Myelodysplastic syndromes (Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top